PMID- 21530500
OWN - NLM
STAT- MEDLINE
DCOM- 20110930
LR  - 20171116
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
VI  - 412
IP  - 15-16
DP  - 2011 Jul 15
TI  - Small dense LDL cholesterol is a robust therapeutic marker of statin treatment in 
      patients with acute coronary syndrome and metabolic syndrome.
PG  - 1423-7
LID - 10.1016/j.cca.2011.04.021 [doi]
AB  - BACKGROUND: Small dense low-density lipoprotein (sd-LDL) is an atherogenic LDL 
      subfraction and often increased in metabolic syndrome (MetS). This study aimed to 
      determine whether sd-LDL cholesterol (sd-LDL-C) is a therapeutic marker of statin 
      treatment in patients with acute coronary syndrome (ACS) and MetS. METHODS: We 
      examined 71 patients with ACS and 50 non-ACS subjects with normal coronary 
      arteries (controls). The patients with ACS were treated with life-style 
      modifications (n=36) or those plus 20mg atorvastatin daily (n=35) for 6 months. 
      We measured sd-LDL-C by a novel detergent-based homogenous assay and calculated 
      buoyant LDL-C (b-LDL-C). RESULTS: The patients with ACS had higher sd-LDL-C than 
      did the controls (30+/-14 vs. 22+/-8 mg/dl, p<0.001). Furthermore, sd-LDL-C was 
      higher in the patients with ACS and MetS (n=31) than in those without MetS (n=40) 
      (35+/-17 vs. 27+/-11 mg/dl, p<0.05). Atorvastatin reduced LDL-C and sd-LDL-C by 31% 
      (102+/-23 to 70+/-28 mg/dl, p<0.0001) and 24% (29+/-15 to 22+/-13 mg/dl, p<0.01). The 
      reduction in sd-LDL-C by atorvastatin was 5.5-fold greater in the patients with 
      ACS and MetS than in those without MetS (p<0.001). Contrary, that in b-LDL-C was 
      similar between the groups. CONCLUSIONS: sd-LDL-C is a superior therapeutic 
      marker of statin treatment in patients with ACS and MetS.
CI  - Copyright (c) 2011 Elsevier B.V. All rights reserved.
FAU - Fukushima, Yoshifumi
AU  - Fukushima Y
AD  - Department of Cardiology, Juntendo University Faculty of Medicine, Tokyo, Japan.
FAU - Hirayama, Satoshi
AU  - Hirayama S
FAU - Ueno, Tsuyoshi
AU  - Ueno T
FAU - Dohi, Tomotaka
AU  - Dohi T
FAU - Miyazaki, Tetsuro
AU  - Miyazaki T
FAU - Ohmura, Hirotoshi
AU  - Ohmura H
FAU - Mokuno, Hiroshi
AU  - Mokuno H
FAU - Miyauchi, Katsumi
AU  - Miyauchi K
FAU - Miida, Takashi
AU  - Miida T
FAU - Daida, Hiroyuki
AU  - Daida H
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110419
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 0 (Biomarkers)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Lipoproteins, LDL)
SB  - IM
MH  - Acute Coronary Syndrome/*blood/drug therapy
MH  - Aged
MH  - Biomarkers/blood
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Lipoproteins, LDL/*blood
MH  - Male
MH  - Metabolic Syndrome/*blood/drug therapy
MH  - Middle Aged
EDAT- 2011/05/03 06:00
MHDA- 2011/10/01 06:00
CRDT- 2011/05/03 06:00
PHST- 2011/02/23 00:00 [received]
PHST- 2011/04/13 00:00 [revised]
PHST- 2011/04/13 00:00 [accepted]
PHST- 2011/05/03 06:00 [entrez]
PHST- 2011/05/03 06:00 [pubmed]
PHST- 2011/10/01 06:00 [medline]
AID - S0009-8981(11)00215-4 [pii]
AID - 10.1016/j.cca.2011.04.021 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2011 Jul 15;412(15-16):1423-7. doi: 10.1016/j.cca.2011.04.021. 
      Epub 2011 Apr 19.